Since its creation in 1997, the company has raised a total of EUR 32M in subsidies and venture funding. Lynx is a leader in the development and application of novel technologies for the discovery of gene expression patterns and genomic variations important to the pharmaceutical, biotechnology and agricultural industries. These technologies are based on the Megaclone technology, Lynx's unique and proprietary cloning procedure, which transforms a sample containing millions of DNA molecules into one made up of millions of micro-beads, each of which carries approximately 100,000 copies of one of the DNA molecules in the sample. These statements include those related to the identification of differentially expressed genes, as well as the potential success of collaboration arrangements. The information in this press release is current as of its release date.
Lynx takes no responsibility to update the information.